Psychocardiology: Chronic Stress and Cardiac Fibrosis Interconnection

Background: Chronic psychological stress is increasingly recognized as a significant contributor to cardiovascular disease, yet its role in structural myocardial remodeling—particularly cardiac fibrosis—remains underappreciated. The emerging field of psychocardiology highlights the intricate interplay between emotional distress, neuroendocrine activation, and myocardial tissue remodeling. Chronic stress triggers persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, leading to elevated levels of cortisol, norepinephrine, and pro-inflammatory cytokines. These neurohumoral changes exert direct and indirect effects on cardiac fibroblasts, promoting extracellular matrix deposition, myofibroblast differentiation, and interstitial fibrosis. Methods and Results: This review consolidates mechanistic evidence from preclinical models and human studies linking chronic stress to myocardial fibrosis. Animal models exposed to prolonged psychosocial stress exhibit increased collagen I/III expression, upregulation of TGF-β signaling, and enhanced ventricular stiffness independent of hemodynamic load. Clinical data show that patients with high perceived stress, depression, or post-traumatic stress disorder (PTSD) have elevated biomarkers of collagen turnover and myocardial strain abnormalities on imaging. Functional MRI and heart rate variability analyses confirm dysregulation of the brain-heart axis in stress-exposed individuals. Interventions targeting stress pathways—such as glucocorticoid receptor antagonists, β-blockers, mindfulness-based therapies, and vagal nerve stimulation—demonstrate antifibrotic and cardioprotective effects. Conclusion: Chronic stress is a potent yet modifiable driver of cardiac fibrosis through sustained neurohumoral and inflammatory activation. Integrating psychological assessment into cardiovascular risk profiling may improve early detection of stress-related myocardial remodeling. Targeting the psychocardiological axis opens new therapeutic avenues to prevent or attenuate fibrosis-driven progression of heart failure and other cardiomyopathies.